NCT02453620View on ClinicalTrials.gov

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 12, 2016

Primary Completion Date

April 22, 2021

Study Completion Date

September 17, 2026

Conditions
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast AdenocarcinomaInvasive Breast CarcinomaMalignant Solid Neoplasm
Interventions
PROCEDURE

Biopsy Procedure

Undergo tissue biopsy

OTHER

Blood Sample

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

DRUG

Entinostat

Given PO

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

OTHER

Pharmacogenomic Study

Correlative studies

OTHER

Pharmacological Study

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (5)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

91010

City of Hope Comprehensive Cancer Center, Duarte

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH